Durvalumab Combined With Chemotherapy and SABR Therapy in Patiënten met Oligogemetastaseerd Non-small Cell Longkanker: A Multicenter Fase 2-Studie

Immunotherapy plus chemotherapy is the standard of care for driver-gene negative metastatic non-small cell lung cancer (NSCLC). Synchronous oligometastatic disease has a better prognosis than extensive metastasis, and the addition of stereotactic ablation body radiotherapy (SABR) results in improved efficacy. However, whether the combination of SABR with immunotherapy and platinum-doublet chemotherapy will lead to long-term disease control or even cure for patients remains unclear.